Pyrimidine-processing enzyme

Pyrimidine-processing enzymes refer to a broad group of enzymes involved in the synthesis, regulation, and degradation of pyrimidine nucleotides, which are essential for DNA and RNA synthesis, cell cycle progression, and various metabolic processes[1][2][3][4][5][9]. Key enzymes in this category include carbamoyl phosphate synthetase II, aspartate transcarbamoylase, dihydroorotate dehydrogenase, and thymidylate synthase[1][3][4][5][9]. These enzymes are fundamental targets in the treatment of a range of diseases, especially cancer and autoimmune disorders, through inhibition of nucleotide biosynthesis[1][2][5][9]. However, "Pyrimidine-processing enzymes" is not a single canonical target but rather a collective term encompassing several distinct enzymes within the pyrimidine metabolic pathway; therefore, it is considered an imprecise or overspecified target name and should be replaced by specific enzyme names for structured data extraction[4][9][3]. Key details: - The biosynthesis pathway includes steps catalyzed by CAD (a multifunctional enzyme with several activities), dihydroorotate dehydrogenase (DHODH), and uridine monophosphate synthase (UMPS)[1][3][9]. - Imbalances or inhibition in the activity of these enzymes can result in cell cycle arrest, impaired DNA replication, and are exploited therapeutically in cancer and immunological diseases[1][2][4]. - Drugs such as leflunomide, PALA, and 5-fluorouracil act on specific pyrimidine-processing enzymes, most often by blocking key steps in nucleotide production[4][9]. Because "Pyrimidine-processing enzymes" does not refer to a single entity but a group, the entry is flagged as "is_incorrect: true". Specific enzyme names (e.g., "Dihydroorotate dehydrogenase" or "Thymidylate synthase") should be used for precise targeting in therapeutic contexts.

Inhibition of nucleotide synthesis; Inhibition of enzyme activity (e.g., DHODH inhibitors, TS inhibitors)